Key reasons GLP-1s require heightened caution in eating disorder populations include: Appetite suppression that may reinforce restrictive behaviors Rapid or significant weight changes that can increase psychological distress Heightened focus on food intake, body cues, or weight-related outcomes Temporary behavioral changes that may mask symptoms rather than address underlying drivers Eating disorders are multifaceted mental health conditions that cannot be effectively treated through appetite or weight changes alone
Individuals who prefer quick, single-nutrient appointments lasting only a few minutes
This review looks at the credentialing, the oral-versus-injectable choice, and the fine print, then closes the loop with the genetic context
By supporting weight loss and healthier lifestyle habits, semaglutide can also help lower the risk of heart disease, stroke, and certain cancers
Fiber, hydration, and probiotic-rich foods may help balance things out
The GLP-1 gastrointestinal injury MDL includes claims involving Novo Nordisk and Eli Lilly products
